Kathleen M. Shannon

Kathleen M. Shannon publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Kathleen M. Shannon sits on this spectrum.

Kathleen M. Shannon D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Kathleen M. Shannon sits on this spectrum.

Best Publications

• Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

  Timothy R. Sampson;Justine W. Debelius;Taren Thron;Stefan Janssen

  3629
  Citations

• A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†

  C. Warren Olanow;Christopher G. Goetz;Jeffrey H. Kordower;A. Jon Stoessl

  1873
  Citations

• Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease

  Christopher B. Forsyth;Kathleen M. Shannon;Jeffrey H. Kordower;Robin M. Voigt

  985
  Citations

• Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People

  David A. Bennett;Laurel A. Beckett;Anne M. Murray;Kathleen M. Shannon

  907
  Citations

• Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  D Aarsland;M Emre;A Lees;W Poewe

  639
  Citations

• Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases†‡§

  Kathleen M. Shannon;Ali Keshavarzian;Hemraj B. Dodiya;Shriram Jakate

  493
  Citations

• Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice

  Paula Perez-Pardo;Hemraj B Dodiya;Phillip A Engen;Christopher B Forsyth

  432
  Citations

• Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease

  Shannon Km;Bennett Jp;Friedman Jh

  400
  Citations

• A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

  I. H. Richard;M. P. McDermott;R. Kurlan;J. M. Lyness

  396
  Citations

• Multicenter Study of Autologous Adrenal Medullary Transplantation to the Corpus Striatum in Patients with Advanced Parkinson's Disease

  Christopher G. Goetz;C. Warren Olanow;William C. Koller;Richard D. Penn

  331
  Citations

• Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.

  Leo P. Kelly;Paul M. Carvey;Ali Keshavarzian;Kathleen M. Shannon

  324
  Citations

• Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.

  Hemraj B. Dodiya;Christopher B. Forsyth;Robin M. Voigt;Phillip A. Engen

  302
  Citations

• Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.

  C. L. Comella;J. Jankovic;K. M. Shannon;J. Tsui

  287
  Citations

• An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype

  Parvoneh Poorkaj;Nancy A. Muma;Victoria Zhukareva;Elizabeth J. Cochran

  256
  Citations

• Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methods

  C G Goetz;C M Tanner;R S Wilson;V S Carroll

  216
  Citations

• Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale

  D. A. Bennett;K. M. Shannon;L. A. Beckett;C. G. Goetz

  213
  Citations

• Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease A Randomized Clinical Trial

  Karl Kieburtz;Barbara C. Tilley;Jordan J. Elm;Debra Babcock

  207
  Citations

• The current clinical management of Huntington's disease.

  Wendy Phillips;Kathleen M. Shannon;Roger A. Barker

  194
  Citations

• Stereotactic pallidotomy for the treatment of Parkinson's disease Efficacy and adverse effects at 6 months in 26 patients

  K. M. Shannon;R. D. Penn;J. S. Kroin;C. H. Adler

  165
  Citations

• A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

  Andrew McGarry;Michael McDermott;Karl Kieburtz;Elisabeth A. DeBlieck

  143
  Citations